OSE Immunotherapeutics Shuffles Leadership to Accelerate 2026-2028 Strategy
Event summary
- Thomas Gidoin promoted to Deputy CEO, adding to his CFO role, effective April 14, 2026.
- Aurore Morello named Chief Scientific Officer, replacing her role as Head of Research.
- Appointments follow CEO Marc Le Bozec's confirmation on March 10, 2026.
- Gidoin to oversee financial strategy and investor relations; Morello to lead R&D innovation.
- Moves align with OSE's 2026-2028 strategic plan focused on immuno-oncology and immuno-inflammation.
The big picture
OSE Immunotherapeutics is consolidating its leadership team to drive its 2026-2028 strategic plan, focusing on immuno-oncology and immuno-inflammation. The appointments of Gidoin and Morello suggest a dual emphasis on financial discipline and scientific innovation, critical for a clinical-stage biotech navigating competitive and capital-intensive markets. The moves come as the company seeks to differentiate itself in a sector increasingly dominated by large players and specialized startups.
What we're watching
- Execution Risk
- Whether the new leadership team can deliver on the ambitious 2026-2028 strategic plan.
- Investor Confidence
- How Thomas Gidoin's expanded role will impact investor relations and financial strategy.
- Scientific Momentum
- The pace at which Aurore Morello can advance OSE's pipeline of immunotherapies.
Related topics